Drug for renal and lung cancer patients headed for the PBS

Opdivo, another very expensive miracle immunotherapy drug, is headed onto the PBS. This is great news for Australians with renal and lung cancer who will benefit from this medication. “From Tuesday, the federal government will subsidise Opdivo so that patients will pay just $38.80 per treatment, or $6.30 for those with a concession card. Up to now, patients have had to fork out about $5000 a course – adding up to more than $130,000 per year.” Read the story here , courtesy of www.sbs.com.au.